Drug profile · INN
hydroxyamphetamine hydrobromide
PAREDRINE
hydroxyamphetamine hydrobromide (PAREDRINE) is a adrenergic receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — hydroxyamphetamine hydrobromide
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
hydroxyamphetamine hydrobromide (PAREDRINE) is a adrenergic receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor agonist
Primary target: Adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is hydroxyamphetamine hydrobromide?
hydroxyamphetamine hydrobromide (PAREDRINE) is a adrenergic receptor agonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for hydroxyamphetamine hydrobromide?
PAREDRINE is a marketed brand name for hydroxyamphetamine hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of hydroxyamphetamine hydrobromide?
hydroxyamphetamine hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.